Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
Shen, Ying , Nitta, Masayuki, Futalan, Diahnn, Treiber, Jeffrey M. , Taich, Zack, Stevens, Deanna M., Wykosky, Jill, Chen, Hong-Zhuan, Becher, Oren J. , Kennedy, Richard D. , Cavenee, Webster K. , Desai, Arshad , Chen, Clark C. , Li, Jie , Steed, Tyler , Taich, Zack, Carter, Bob S. , Esashi, Fumiko , Sarkaria, Jann N. , Furnari, Frank B.

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 14 | Pages: 11751-11767

10.18632/oncotarget.3996 | PMID 26059434 Get It

A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion
Saravia-Butler, Amanda , Buzhardt, Michele L. Scotti, Erdogan, Eda, Li, Shuhua , Inman, Kristin S. , Fields, Alan P. , Murray, Nicole R. , Butler, Amanda M, Buzhardt, Michele Scotti

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 17 | Pages: 15297-15310

10.18632/oncotarget.3812 | PMID 25915428 Get It

Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer
Xia, Shu , Du, Meijun , Nandy, Debashis, Yuan, Tiezheng , Guo, Yongchen, Tschannen, Michael, See, William A., Kilari, Deepak , Wang, Xuexia , Hovey, Raymond , Huang, Chiang‐Ching , Kohli, Manish , Dittmar, Rachel L. , Lee, Adam, Wang, Yuan , Worthey, Elizabeth A. , Jacob, Howard J. , Wang, Liang

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 18 | Pages: 16411-16421

10.18632/oncotarget.3845 | PMID 25915538 Get It

Mutated Fanconi anemia pathway in non-Fanconi anemia cancers
Shen, Yihang , Lee, Yuan‐Hao , Panneerselvam, Jayabal, Loo, Lenora W. M. , Fei, Peiwen, Zhang, Jun

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 24 | Pages: 20396-20403

10.18632/oncotarget.4056 | PMID 26015400 Get It

Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression
Polo, María Laura, Riggio, Marina, May, María , Rodriguez, María Jimena , Perrone, María Cecilia , Stallings‐Mann, Melody , Kaen, Diego, Frost, Marlene H., Lanari, Claudia , Frost, Marlene, Boughey, Judy, Radisky, Derek, Polo, María L. , Goetz, Matthew P. , Boughey, Judy C. , Radisky, Derek C. , Novaro, Virginia , Lanari, Claudia

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 26 | Pages: 22081-22097

10.18632/oncotarget.4203 | PMID 26098779 Get It

Assessment of folate receptor-β expression in human neoplastic tissues
Shen, Jiayin , Putt, Karson S. , Visscher, Daniel W., Cohen, Cynthia , Sandusky, George E. , Feng, Yang, Dimitrov, Dimiter S. , Murphy, Linda, Murphy, Linda Suk-Ling , Singhal, Sunil Kumar , Low, Philip S.

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 16 | Pages: 14700-14709

10.18632/oncotarget.3739 | PMID 25909292 Get It

Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines
Hanavan, Paul D., Katchman, Benjamin A. , Faigel, Douglas O. , Ho, Thai H. , Ma, Chen-Ting, Sergienko, Eduard , Meurice, Nathalie , Lake, Douglas F. , Petit, Joachim L. , Borges, Chad R. , Ho, Thai

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 21 | Pages: 18418-18428

10.18632/oncotarget.4099 | PMID 26158899 Get It

Coagulation changes during lower body negative pressure and blood loss in humans
Johnson, Blair D. , Curry, Timothy B. , Cap, Andrew P., Convertino, Víctor A. , Joyner, Michael J. , van Helmond, Noud, Helmond, Noud van , Cap, Andrew P., Johnson, Blair D , Joyner, Michael J

American Journal of Physiology-Heart and Circulatory Physiology | September 15, 2015 | Volume: 309 | Issue: 9 | Pages: H1591-H1597

10.1152/ajpheart.00435.2015 | PMID 26371166 Get It

We tested the hypothesis that markers of coagulation activation are greater during lower body negative pressure (LBNP) than those obtained during blood loss (BL). We assessed coagulation using both standard clinical tests and thrombelastography (TEG) in 12 men who performed a LBNP and BL protocol in a randomized order. LBNP consisted of 5-min stages at 0, −15, −30, and −45 mmHg of suction. BL included 5 min at baseline and following three stages of 333 ml of blood removal (up to 1,000 ml total). Arterial blood draws were performed at baseline and after the last stage of each protocol. We found that LBNP to −45 mmHg is a greater central hypovolemic stimulus versus BL; therefore, the coagulation markers were plotted against central venous pressure (CVP) to obtain stimulus-response relationships using the linear regression line slopes for both protocols. Paired t-tests were used to determine whether the slopes of these regression lines fell on similar trajectories for each protocol. Mean regression line slopes for coagulation markers versus CVP fell on similar trajectories during both protocols, except for TEG α° angle (−0.42 ± 0.96 during LBNP vs. −2.41 ± 1.13°/mmHg during BL; P < 0.05). During both LBNP and BL, coagulation was accelerated as evidenced by shortened R-times (LBNP, 9.9 ± 2.4 to 6.2 ± 1.1; BL, 8.7 ± 1.3 to 6.4 ± 0.4 min; both P < 0.05). Our results indicate that LBNP models the general changes in coagulation markers observed during BL.
Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT‐AF)
Kim, Sunghee , Thomas, Laine , Fonarow, Gregg C. , Holmqvist, Fredrik , Kowey, Peter R. , Mahaffey, Kenneth W. , Reiffel, James A. , Chang, Paul, Piccini, Jonathan P. , Patients, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Investigators and, Steinberg, Benjamin A. , Gersh, Bernard J. , Hylek, Elaine M. , Naccarelli, Gerald V. , Peterson, Eric D. , Patients, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Investigators and

Journal of the American Heart Association | September 15, 2015 | Volume: 4 | Issue: 9 | Pages: No page available

10.1161/jaha.115.002031 | PMID 26370445 Get It

Background Most patients with atrial fibrillation ( AF ) require rate control; however, the optimal target heart rate remains under debate. We aimed to assess rate control and subsequent outcomes among patients with permanent AF . Methods and Results We studied 2812 US outpatients with permanent AF in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. Resting heart rate was measured longitudinally and used as a time‐dependent covariate in multivariable Cox models of all‐cause and cause‐specific mortality during a median follow‐up of 24 months. At baseline, 7.4% (n=207) had resting heart rate <60 beats per minute (bpm), 62% (n=1755) 60 to 79 bpm, 29% (n=817) 80 to 109 bpm, and 1.2% (n=33) ≥110 bpm. Groups did not differ by age, previous cerebrovascular disease, heart failure status, CHA 2 DS 2 ‐ VAS c scores, renal function, or left ventricular function. There were significant differences in race ( P =0.001), sinus node dysfunction ( P =0.004), and treatment with calcium‐channel blockers ( P =0.006) and anticoagulation ( P =0.009). In analyses of continuous heart rates, lower heart rate ≤65 bpm was associated with higher all‐cause mortality (adjusted hazard ratio [ HR ], 1.15 per 5‐bpm decrease; 95% CI , 1.01 to 1.32; P =0.04). Similarly, increasing heart rate >65 bpm was associated with higher all‐cause mortality (adjusted HR , 1.10 per 5‐bpm increase; 95% CI , 1.05 to 1.15; P <0.0001). This relationship was consistent across endpoints and in a broader sensitivity analysis of permanent and nonpermanent AF patients. Conclusions Among patients with permanent AF , there is a J‐shaped relationship between heart rate and mortality. These data support current guideline recommendations, and clinical trials are warranted to determine optimal rate control. Clinical Trial Registration URL : http://clinicaltrials.gov/ . Unique identifier: NCT01165710.